



# Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

## Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,  
Opp. PCI, Ankleshwar – 393 002,  
Gujarat, India  
Tel : (02646) 220774  
Fax : (02646) 251291  
Web: www.samratpharmachem.com      CIN: L24230GJ1992PLC017820

## Corporate Office

701/702, Business Square,  
M. A. Road, Andheri (West),  
Mumbai – 400 058, India.  
Tel : (91-22) 26701050/1/2  
Fax : (91-22) 26701053  
Email: contact@samratpharmachem.in

**July 31, 2020**

To,  
**Department of Corporate Services,  
BSE Limited**  
P J Towers,  
Dalal Street,  
Mumbai - 400 001.

**Scrip Code: 530125**

Dear Sir,

**Sub: Outcome of the Board Meeting of the Company held today**

We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Friday, July 31, 2020, the Board has considered and adopted the attached Audited Financial Results of the Company for the year ended March 31, 2020, which is enclosed herewith along with the Auditor's Report and Declaration for Unmodified Opinion on the Financial Results of the Company.

The meeting of the Board of Directors of the Company commenced at 18:00 hrs and concluded at 19:00 hrs.

Kindly inform all your members.

Thanking you,

Yours faithfully,  
**For Samrat Pharmachem Limited**

**Nishant Kankaria**  
**Company Secretary & Compliance Officer**



# Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd Office : Plot No. A2/3445, GIDC, Phase 4, Ankleshwar - 393 002, Gujarat (Website: www.samratpharmachem.com)

Corp Office : 701/702 Business Square, M. A. Road, Andheri (West), Mumbai - 400 058 (CIN: L24230GJ1992PLC017820)

Particulars	(Rs. in Lakhs)				
	Quarter Ended			Year Ended	
	31-Mar-20 (Audited)	31-Dec-19 (Unaudited)	31-Mar-19 (Audited)	31-Mar-20 (Audited)	31-Mar-19 (Audited)
<b>Statement of Standalone Audited Results for the Quarter and for the Year Ended 31 MARCH, 2020</b>					
1 (a). Revenue from Operations	3,027.81	3,515.56	3,642.88	13,745.25	11,113.64
(b). Other Income	7.74	3.53	17.62	57.22	45.67
Total Revenue	3,035.55	3,519.09	3,660.50	13,802.47	11,159.31
2. Expenses					
a) Cost of materials consumed	2,941.95	3,724.41	3,220.54	13,179.80	10,353.24
b) Purchase of Traded Goods	0.00	0.00	0.00	0.00	0.00
c) Changes in inventories of FG, WIP & Stock in trade	-155.93	-419.09	54.82	-618.06	-90.93
d) Employee Costs	50.88	34.19	51.00	144.39	138.36
e) Finance Cost	33.42	25.02	34.17	97.83	105.84
f) Depreciation & Amortisation expense	10.83	10.61	10.40	42.63	41.77
g) Other Expenses	96.73	91.74	120.01	376.16	395.27
(i) Manufacturing Expenses	59.30	59.37	56.13	223.66	219.47
(ii) Administration Expenses	12.75	14.07	29.31	64.09	75.68
(iii) Selling & Distribution Expenses	24.68	18.30	34.57	88.41	100.12
Total Expenses	2,977.88	3,466.88	3,490.94	13,222.75	10,943.55
3. Profit before exceptional items and tax	57.67	52.21	169.56	579.72	215.76
4. Exceptional Items	-1.20	0.00	0.00	-1.20	0.00
5. Profit before extraordinary items & tax	56.47	52.21	169.56	578.52	215.76
6. Extraordinary items	0.00	0.00	0.00	0.00	0.00
6. Profit before tax	56.47	52.21	169.56	578.52	215.76
6. Tax expense					
a) Current Tax	-45.13	-11.07	-53.40	-172.51	-61.46
b) Deferred Tax	28.00	5.97	13.92	17.69	-0.75
Total Tax Expense	-17.13	-5.10	-39.48	-154.82	-62.21
7. Profit (Loss) for the period from continuing operations	39.34	47.11	130.08	423.70	153.55
8. Profit / (Loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
9. Tax expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
10. Profit / (Loss) from discontinuing operations after tax	0.00	0.00	0.00	0.00	0.00
11. Profit / (Loss) for the period	39.34	47.11	130.08	423.70	153.55
12. Other Comprehensive Income (OCI)	0.00	0.00	0.00	0.00	0.00
13. Total Comprehensive Income for the period	39.34	47.11	130.08	423.70	153.55
14. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97	308.97	308.97	308.97
15. Earnings per equity share (not annualized)					
a) Basic	1.27	1.52	4.21	13.71	4.97
b) Diluted	1.27	1.52	4.21	13.71	4.97



# Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

<b>Standalone Statement of Assets and Liabilities</b>		
<b>Particulars</b>	<b>As at 31-Mar-20 (Audited)</b>	<b>As at 31-Mar-19 (Audited)</b>
<b>ASSETS</b>		
<b>Non-Current Assets</b>		
Property, Plant and Equipment	718.15	685.28
Capital work-in-progress	108.08	0.00
Intangible assets	0.39	1.02
Intangible assets under development	0.00	0.00
<b>Financial Assets</b>		
Investments	0.00	0.00
Loans	16.87	9.68
Deferred tax assets (net)	0.00	0.00
Other non-current assets	23.33	50.82
<b>Total Non Current Assets</b>	<b>866.82</b>	<b>746.80</b>
<b>Current Assets</b>		
Inventories	1,876.74	792.96
<b>Financial Assets</b>		
Investments	0.10	0.10
Trade Receivables	2,781.28	2,104.79
Cash and Cash Equivalents	117.18	224.62
Loans	2.34	2.46
Other Financial Assets	0.00	0.00
Other current assets	190.40	150.93
<b>Total Current Assets</b>	<b>4,968.04</b>	<b>3,275.86</b>
<b>Total Assets</b>	<b>5,834.86</b>	<b>4,022.66</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity Share capital	308.97	308.97
Other Equity	2,121.40	1,697.72
<b>Total Equity</b>	<b>2,430.37</b>	<b>2,006.69</b>
<b>Non-Current Liabilities</b>		
<b>Financial Liabilities</b>		
Borrowings	0.00	31.28
Provisions	0.00	0.00
Deferred Tax Liabilities (Net)	14.48	32.17
Other Non-Current Liabilities	0.00	19.63
<b>Total Non-Current liabilities</b>	<b>14.48</b>	<b>83.08</b>
<b>Current Liabilities</b>		
<b>Financial Liabilities</b>		
Borrowings	909.67	577.16
Trade Payables	2,314.61	1,265.63
Other Financial Liabilities	0.00	0.00
Other Current Liabilities	43.89	53.40
Provisions	121.84	36.70
<b>Total Current Liabilities</b>	<b>3,390.01</b>	<b>1,932.89</b>
<b>Total Liabilities</b>	<b>5,834.86</b>	<b>4,022.66</b>



# Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

## Notes

1. The above results were reviewed by the Audit Committee of the Board of Directors.
2. The above results have been taken on record by the Board of Directors at its Meeting held on Friday, 31 July 2020 at the Corporate Office of the Company.
3. The figures of the quarter ended 31 Mar 2020 and 31 Mar 2019 are the balancing figures between the audited figures in respect of full financial years and the published (unaudited) up to the third quarter of relevant financial year.
4. The Company manufactures pharmaceutical chemicals, which is a single business segment.
5. The figures for the previous period have been regrouped where necessary to conform to current period's classification.

By order of the Board of Directors  
For Samrat Pharmachem Limited

Rajesh Mehta  
Executive Director

Place : Mumbai  
Date : 31 July 2020





### INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of,  
**Samrat Pharmachem Limited**

#### **Report on the audit of the Annual Financial Results**

##### **Opinion**

We have audited the accompanying annual financial results of Samrat Pharmachem Limited ('the Company') for the year ended 31 March 2020 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid annual financial results:

- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (Ind AS) prescribed under section 133 of The Companies Act, 2013 (the Act), read with relevant rules issued there under and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended 31 March 2020.

##### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Annual Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Financial Statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the Annual Financial Results.

##### **Management's & Board of Director's Responsibility for the Annual Financial Results**

These Annual Financial Results have been prepared on the basis of the Annual Financial Statements. The Company's Management and the Board of Directors are responsible for the preparation and presentation of these Annual Financial Results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Annual Financial Results that give a true and fair view & are free from material misstatement, whether due to fraud or error.

In preparing the Annual Financial Results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.



### **Auditor's Responsibility**

Our objectives are to obtain reasonable assurance about whether the Annual Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Annual Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of Financial Statements on whether the company has adequate internal financial controls with reference to Financial Statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the Annual Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Financial Results, including the disclosures, and whether the Annual Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

### **Other Matter**

The Annual Financial Results include the results for the quarter ended 31 March 2020 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

**UDIN : 20108135AAAABC3423**

For Shah & Savla LLP  
Chartered Accountants  
FRN :109364W/W100143



**MIRAL H NAGDA**  
**(PARTNER)**  
Membership No. 108135



Place: Mumbai  
Date : 31<sup>st</sup> July, 2020



# Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

## Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,  
Opp. PCI, Ankleshwar – 393 002,  
Gujarat, India  
Tel : (02646) 220774  
Fax : (02646) 251291  
Web: www.samratpharmachem.com      CIN: L24230GJ1992PLC017820

## Corporate Office

701/702, Business Square,  
M. A. Road, Andheri (West),  
Mumbai – 400 058, India.  
Tel : (91-22) 26701050/1/2  
Fax : (91-22) 26701053  
Email: contact@samratpharmachem.in

**31 July, 2020**

To,  
**Department of Corporate Services,  
BSE Limited**  
P J Towers,  
Dalal Street,  
Mumbai - 400 001.

**Sub: Declaration with respect to Audit report with unmodified opinion for the financial year ended March 31, 2020**

Dear Sir,

Pursuant to clause 4.1 of SEBI circular no CIR/CFD/CMD/56/2016 dated May 27, 2016, we hereby declare that the Statutory Auditors of the company M/s Shah & Savla LLP, Chartered Accountants, Mumbai, have issued the audit report under the Companies Act 2013 on the Standalone Financial Results of the Company as prepared under SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015 for the financial year ended March 31, 2020, with unmodified opinion.

Request to take note of the above

Thanking You.

Yours faithfully,  
**For Samrat Pharmachem Limited**

**Nishant Kankaria**  
**Company Secretary & Compliance Officer**